Invivyd’s (IVVD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a report released on Tuesday, Benzinga reports. They currently have a $15.00 price objective on the stock.

Invivyd Trading Down 4.4 %

Shares of NASDAQ:IVVD opened at $0.81 on Tuesday. The stock has a fifty day simple moving average of $1.08 and a two-hundred day simple moving average of $2.14. The stock has a market capitalization of $97.12 million, a price-to-earnings ratio of -0.44 and a beta of 0.61. Invivyd has a 12-month low of $0.81 and a 12-month high of $5.20.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.03). The firm had revenue of $2.26 million during the quarter, compared to analysts’ expectations of $4.91 million. As a group, equities research analysts predict that Invivyd will post -0.63 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of IVVD. Chase Investment Counsel Corp purchased a new position in shares of Invivyd in the first quarter worth $271,000. SG Americas Securities LLC purchased a new position in shares of Invivyd in the first quarter worth $56,000. Vanguard Group Inc. grew its holdings in shares of Invivyd by 3.9% in the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after acquiring an additional 97,496 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Invivyd in the first quarter worth $905,000. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Invivyd by 21.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock worth $1,933,000 after acquiring an additional 77,603 shares during the period. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.